Grapefruit juice found to give cancer treatment a boost

August 10, 2009 By Vanessa McMains

When Albina Duggan of Bourbonnais, Ill., was diagnosed with Stage IV cancer, it had spread from her liver to her spine and lymph nodes.

"(The doctor) told me I had three years -- if lucky, five -- to live," she said. Having endured four surgeries and intensive radiation treatment, Duggan enrolled in clinical trials as a last resort.

Five years later, the 41-year-old mother of four has defied expectations: Her tumors have shrunk by half and doctors no longer are setting limits on her life expectancy.

Duggan attributes her new hope to an unusual cancer treatment being tested at the University of Chicago -- the drug rapamycin, supplemented by grapefruit juice.

Unlike most beverages, grapefruit juice contains a chemical that boosts the potency of many drugs in the body. To avoid a dangerously high dose of medication, patients are often advised to not wash down pills with grapefruit juice.

University of Chicago cancer researcher Dr. Ezra Cohen wondered if that quality could be used for good -- if drinking the juice could boost the effectiveness of cancer drugs.

For example, rapamycin and related drugs normally must be taken daily to be effective against cancer. Taking it once a week would lower the cost and decrease adverse side effects, including suppression of the immune system and .

This spring, at the American Association for Cancer Research's 100th annual meeting in Denver, Cohen presented early results finding that drug levels in patients taking rapamycin once a week and drinking 8 ounces of grapefruit juice every day were similar to the levels that would be expected from taking the drug daily without juice.

Cohen says about a third of the 25 patients enrolled in the study long enough to be evaluated have seen their tumors stop growing while on the treatment, with Duggan the most dramatic example.

"Mrs. Duggan amazed everyone in the study," he said.

Most of the other participants have cancers that have reacted well to rapamycin in past studies, such as kidney and prostate cancer. Duggan's rare cancer, which involves blood vessels, apparently is also responsive to the drug.

Rapamycin prevents cells from multiplying, which is important for keeping cancer growth in check. But because an enzyme in the intestine breaks down the drug, only a fraction of the rapamycin a patient swallows gets into the system, Cohen said.

Grapefruit juice contains chemicals that block this enzyme, which he said "normally protects us from other toxic chemicals and metabolizes them to harmless byproducts." These chemicals, called furanocoumarins, prevent rapamycin from being broken down so the body can absorb more of it.

However, not just any grapefruit juice will work. The grocery-store grapefruit juice Cohen initially used did not cause an increase of the rapamycin levels in the blood. "We were scratching our heads trying to figure out what was wrong," he said.

By a stroke of luck the Florida Department of Citrus saw a report about Cohen's work on television. The department contacted Cohen and told him the key chemicals in grapefruit juice have a short shelf-life and can break down during the time it takes to process and sell the juice.

The citrus department sent Cohen a more potent juice that had been freshly frozen, which turned out to be effective for raising drug levels in the blood.

Dr. Brian Rini of the Cleveland Clinic Taussig Cancer Institute cautioned people against thinking of grapefruit juice as an all-purpose booster. Certain medications, such as blood-pressure medicines, can be unsafe when taken with grapefruit juice. "It can elevate drug levels for good or bad," he said.

Still, he praised Cohen for helping to find ways to deliver drugs that are cheaper and more convenient for patients.

"The University of Chicago has led the way in finding more effective ways to use cancer drugs," Rini said. "You have the right approach from people who know what they are doing."

Duggan said that when she was enrolled in other clinical trials with different cancer drugs, she experienced sore legs and feet, rashes and hair loss. With this combination, though, "side effects are minimal. I feel healthy and full of energy," she said.

Duggan said she walks three miles daily. "Once a week I take my rapamycin and that is the day that is hardest because I feel fatigued, but I sleep it off," said Duggan, who has been enrolled in the trial since March 2008.

The typical monthly cost for rapamycin treatment is $1,000, but taking less frequent doses with brings the price down to about $250, Cohen said.

Thrilled with her treatment, Duggan said her now is "indefinite."

"There is nothing in my charts that will point to any number," she said. "I might outlive everybody."


(c) 2009, Chicago Tribune.
Visit the Chicago Tribune on the Internet at
Distributed by McClatchy-Tribune Information Services.

Related Stories

Recommended for you

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Suicide molecules kill any cancer cell

October 19, 2017
Small RNA molecules originally developed as a tool to study gene function trigger a mechanism hidden in every cell that forces the cell to commit suicide, reports a new Northwestern Medicine study, the first to identify molecules ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

Fundamental research enhances understanding of major cancer gene

October 19, 2017
New research represents a promising step towards better understanding of a key cancer gene. A long-running collaboration between researchers at the Babraham Institute, Cambridge and the AstraZeneca IMED Biotech Unit reveals ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.